Circulation, Vol 56, 889-890, Copyright © 1977 by American Heart Association
JW Mason, ME Billingham and JP Friedman
Methysergide (Sansert) is known to cause mitral and aortic valvular
fibrosis and dysfunction, but has generally not been known to damage right
heart valves or the myocardium, and cardiac fibrosis has not been
considered to be a risk if therapy is intermittently interrupted. The woman
who is the subject of this case report developed catheterization- proven
severe tricuspid and moderate aortic and mitral regurgitation during
noncontinuous therapy with methysergide. In addition, right ventricular
endomyocardial biopsy revealed extensive endocardial and intramyocardial
fibrosis.
ARTICLES
Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis
This article has been cited by other articles:
![]() |
R. J. Shemin Tricuspid Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1111 - 1128. [Full Text] |
||||
![]() |
R. J. Shemin Tricuspid Valve Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1001 - 1015. [Full Text] |
||||
![]() |
J. A. Caccitolo, H. M. Connolly, D. S. Rubenson, T. A. Orszulak, and H. V. Schaff Operation for anorexigen-associated valvular heart disease J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 656 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Kushwaha, J. T. Fallon, and V. Fuster Restrictive Cardiomyopathy N. Engl. J. Med., January 23, 1997; 336(4): 267 - 276. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1977 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |